Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Suppressors, or silencers, are popular with many recreational shooters, as they effectively reduce a firearm’s noise and muzzle flash upon discharge. These devices are also controversial ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

New USCIS guidelines have sparked confusion among Indian visa holders, but primarily affect undocumented individuals. Non-resident Indians with valid visas, including workers, students ...

An agrivoltaics power plant on the plateau of Guizhou province, southwestern China, has been connected to the grid using Trinasolar Vertex N 720W series modules. With a total capacity of 67.5MW ...

(Freepik) Vertex Ventures’ Southeast Asia and India-focused fund has ramped up its investment activity in India, with a focused approach on AI-led businesses, fintech, and consumer brands.